ArticleBMC infectious diseases2026
CD169 expression of CD14
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune Profiling and Rapid Molecular Diagnostics in Severe Respiratory Infections and Sepsis: The Potential Clinical Perspective of CD169 and CD64.Microorganisms · 2026Article
- A Nomogram Integrating CD169%, Neutrophil CD64 Index, and C-Reactive Protein for Differential Diagnosis of Mixed Respiratory Tract Infections.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have indicated a strong association between CD169 and HIV-1 infection, showing significant elevation of CD169 during infection and viral replication. This study aimed to investigate whether CD169 could serve as a biomarker for the early diagnosis of HIV-1 infection.
methodsWe recruited patients with acute people with HIV(PWH), ART-treated PWH and HIV-1 negative volunteers. Clinical data and peripheral blood samples were collected. CD169 expression on CD14+ monocytes was detected by flow cytometry, and soluble CD169 in plasma was assayed to investigate its relationship with HIV-1 infection and disease progression.
resultsOur study detected a high proportion of CD169+CD14+ monocytes in individuals with acute PWH. Furthermore, we observed that CD169 expression levels were elevated in PWH who had stopped taking their medication.
conclusionThe discovery of CD169 expression in CD14+ monocytes as a biomarker for early HIV-1 infection or AIDS diagnosis offers new possibilities for early intervention and treatment, potentially improving clinical outcomes for PWH. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.